Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanubrutinib - BeiGene

Next Previous
Drug Profile

Zanubrutinib - BeiGene

Alternative Names: BGB-3111; BRUKINSA

Latest Information Update: 18 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Amides; Antineoplastics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma
  • Preregistration Chronic lymphocytic leukaemia
  • Phase III Waldenstrom's macroglobulinaemia
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma
  • Phase I B-cell lymphoma

Most Recent Events

  • 16 Dec 2019 Updated efficacy and adverse event data from the phase III ASPEN trial in Waldenstrom's macroglobulinemia released by BieGene
  • 08 Dec 2019 Efficacy and safety data from a phase I/II trial in Chronic lymphocytic leukemia released by Beigene
  • 08 Dec 2019 Efficacy and safety data from a phase Ib trial in B-cell lymphoma released by Beigene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top